ImageneBio (IMA) Q4 2025 earnings summary

Executive summary

• Ongoing Phase 2b ADAPTIVE trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline data expected in 2027; favorable safety profile observed to date.

• Protocol amendment submitted to expand dosing regimens, evaluate loading doses, and optimize patient-friendly intervals.

• Key leadership additions in 2025–2026, including a new Chief Medical Officer and CEO.

• Company formed via reverse merger and $75M private placement in July 2025.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $135.3M as of December 31, 2025, up from $12.1M at year-end 2024, primarily due to the merger and private placement.

• R&D expenses for Q4 2025 were $3.3M, down from $3.8M in Q4 2024.

• G&A expenses for Q4 2025 were $5.2M, up from $2.4M in Q4 2024, mainly due to merger-related costs and increased personnel expenses.

• Net loss for Q4 2025 was $6.9M, compared to $4.8M in Q4 2024; full-year net loss attributable to common stockholders was $52.4M, up from $48.4M in 2024.

• License revenue for 2025 was $0.8M, down from $3.5M in 2024.

Outlook and guidance

• ADAPTIVE trial enrollment is on track, with topline data expected in 2027.

• Continued focus on expanding safety database and differentiating IMG-007’s efficacy and safety profile.

• Ongoing evaluation of Kaposi's sarcoma risk and OX40/OX40L signaling in the patient population.